Awards for “TEVA PHARMACEUTICALS USA, INC.”
25 awards on this page · sorted by amount · page 19
| Award ID | Recipient | Awarding agency | Amount | Start | End | NAICS | Description |
|---|---|---|---|---|---|---|---|
| SPE2DP23F2848 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $152.7K | 2023-03-22 | 2023-03-28 | 325412 | 8509779168!ADENOVIRUS TYPE 4 A |
| SPE2DP23F1529 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $152.7K | 2023-01-18 | 2023-01-24 | 325412 | 8509645247!ADENOVIRUS TYPE 4 A |
| A063 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $148.11K | 2008-09-26 | 2008-09-29 | 325411 | 4508751780!AMOXICILL |
| SPE2DP23F0890 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $146.82K | 2022-12-06 | 2022-12-20 | 325412 | 8509568681!ADENOVIRUS TYPE 4 A |
| SPE2DP22F6745 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $146.82K | 2022-08-18 | 2022-08-30 | 325412 | 8509324192!ADENOVIRUS TYPE 4 A |
| SPE2DP22F6114 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $146.82K | 2022-07-18 | 2022-07-26 | 325412 | 8509243572!ADENOVIRUS TYPE 4 A |
| SPE2DP22F4647 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $146.82K | 2022-05-17 | 2022-05-24 | 325412 | 8509104947!ADENOVIRUS TYPE 4 A |
| SPE2DP22F4076 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $146.82K | 2022-04-19 | 2022-04-26 | 325412 | 8509034790!ADENOVIRUS TYPE 4 A |
| SPE2DP22F2575 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $146.82K | 2022-02-10 | 2022-03-01 | 325412 | 8508862676!ADENOVIRUS TYPE 4 A |
| SPE2DP22F2115 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $146.82K | 2022-01-18 | 2022-01-25 | 325412 | 8508811865!ADENOVIRUS TYPE 4 A |
| SPE2DP22F1646 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-12-22 | 2021-12-28 | 325412 | 8508767610!ADENOVIRUS TYPE 4 A |
| SPE2DP22F1325 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-12-07 | 2021-12-14 | 325412 | 8508730891!ADENOVIRUS TYPE 4 A |
| SPE2DP22F0705 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-11-09 | 2021-11-16 | 325412 | 8508669969!ADENOVIRUS TYPE 4 A |
| SPE2DP21F6152 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-09-09 | 2021-09-28 | 325412 | 8508510061!ADENOVIRUS TYPE 4 A |
| SPE2DP21F6151 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-09-09 | 2021-09-28 | 325412 | 8508510060!ADENOVIRUS TYPE 4 A |
| SPE2DP21F6150 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-09-09 | 2021-09-28 | 325412 | 8508509888!ADENOVIRUS TYPE 4 A |
| SPE2DP21F6149 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-09-09 | 2021-09-28 | 325412 | 8508509883!ADENOVIRUS TYPE 4 A |
| SPE2DP21F5512 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-08-11 | 2021-08-24 | 325412 | 8508435923!ADENOVIRUS TYPE 4 A |
| SPE2DP21F4958 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-07-13 | 2021-07-20 | 325412 | 8508354092!ADENOVIRUS TYPE 4 A |
| SPE2DP21F3779 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-05-06 | 2021-05-25 | 325412 | 8508191755!ADENOVIRUS TYPE 4 A |
| SPE2DP21F3778 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-05-06 | 2021-05-25 | 325412 | 8508191754!ADENOVIRUS TYPE 4 A |
| SPE2DP21F2624 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-03-10 | 2021-03-23 | 325412 | 8508044915!ADENOVIRUS TYPE 4 A |
| SPE2DP21F2623 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-03-10 | 2021-03-23 | 325412 | 8508044864!ADENOVIRUS TYPE 4 A |
| SPE2DP21F2619 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-03-10 | 2021-03-23 | 325412 | 8508044724!ADENOVIRUS TYPE 4 A |
| SPE2DP21F2287 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-02-22 | 2021-02-23 | 325412 | 8508003637!ADENOVIRUS TYPE 4 A |